Free Trial
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel
OTCMKTS:CHGCY

Chugai Pharmaceutical 4/24/2025 Earnings Report

Chugai Pharmaceutical logo
$26.98 +0.57 (+2.16%)
As of 05/6/2026 03:59 PM Eastern
ProfileEarnings HistoryForecast

Chugai Pharmaceutical EPS Results

Actual EPS
$0.19
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Chugai Pharmaceutical Revenue Results

Actual Revenue
$1.89 billion
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Chugai Pharmaceutical Announcement Details

Quarter
Date
4/24/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Chugai Pharmaceutical's next earnings date is estimated for Friday, July 24, 2026, based on past reporting schedules.

Conference Call Resources

Chugai Pharmaceutical Earnings Headlines

Chugai Pharmaceutical Co., Ltd. (CHGCY) Q4 2025 Earnings Call Transcript
January 29, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4863778-chugai-pharmaceutical-co-ltd-chgcy-q4-2025-earnings-call-transcript
Chugai Reports Positive Data From TEIEN Study Of Port Delivery System With Ranibizumab In NAMD & DME
November 25, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-11/67067501-chugai-reports-positive-data-from-teien-study-of-port-delivery-system-with-ranibizumab-in-namd-dme-020.htm
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.tc pixel
 |  Brownstone Research (Ad)
Chugai Pharmaceutical to Merge with Renalys Pharma to Boost Kidney Disease Drug Development
November 18, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/chugai-pharmaceutical-to-merge-with-renalys-pharma-to-boost-kidney-disease-drug-development/ar-AA1QF83C
Rani Therapeutics Shares Double After Deal With Chugai Pharma
October 17, 2025  |  marketwatch.comhttps://www.marketwatch.com/story/rani-therapeutics-shares-double-after-deal-with-chugai-pharma-ec8486c7
Rani Therapeutics surges on Chugai licensing deal, private placement
October 17, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/rani-therapeutics-surges-on-chugai-licensing-deal-private-placement/ar-AA1OFNCw
See More Chugai Pharmaceutical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Chugai Pharmaceutical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Chugai Pharmaceutical and other key companies, straight to your email.

About Chugai Pharmaceutical

Chugai Pharmaceutical (OTCMKTS:CHGCY) Co., Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics. One of its best-known products is tocilizumab (marketed in many territories through collaborative arrangements), reflecting the company’s capabilities in immunology and antibody engineering. Chugai’s product portfolio and pipeline include both in-house assets and programs developed in collaboration with external partners, demonstrating a mix of internal R&D and strategic alliances to advance new medicines.

Chugai maintains a long-standing strategic partnership with the Roche Group and operates primarily in the Japanese market while leveraging global commercialization channels through alliances. The company supports clinical development and manufacturing activities in Japan and engages with international partners to expand the reach of its therapies. Chugai is managed by a professional leadership and scientific team with experience in pharmaceutical R&D and commercial operations, and it positions itself as a research-oriented company within the global biopharmaceutical landscape.

View Chugai Pharmaceutical Profile
Earnings Tools